Genex Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.08 M
as on 24-10-2024
- Company Age 20 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -20.22%
(FY 2023)
- Profit -25.14%
(FY 2023)
- Ebitda -29.05%
(FY 2023)
- Net Worth 15.77%
(FY 2023)
- Total Assets 22.13%
(FY 2023)
About Genex Life Sciences
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.08 M, as per Ministry of Corporate Affairs (MCA) records.
Ashwinkumar Bellare, Rajeev Puri, and Suresh Kapoor serve as directors at the Company.
- CIN/LLPIN
U73100MH2004PTC147750
- Company No.
147750
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2004
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Genex Life Sciences Private Limited offer?
Genex Life Sciences Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, PCR Machine.
Who are the key members and board of directors at Genex Life Sciences?
Board Members(3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Suresh Kapoor | Director | 29-Jul-2004 | Current |
Ashwinkumar Bellare | Director | 29-Jul-2004 | Current |
Rajeev Puri | Director | 29-Jul-2004 | Current |
Financial Performance and Corporate Structure Insights of Genex Life Sciences.
Genex Life Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 20.22% decrease. The company also saw a substantial fall in profitability, with a 25.14% decrease in profit. The company's net worth Soared by an impressive increase of 15.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Genex Life Sciences?
In 2023, Genex Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genex Life Sciences?
Unlock and access historical data on people associated with Genex Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genex Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genex Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.